Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Baseline disease characteristics (median values) in anti-CCP and ACPA reactivity-positive versus reactivity-negative patients

From: The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy

  ESR CRP DAS SJC44 RAI US GS US PD vdHSS E vdHSS JSN vdHSS T
   p   p   p   p   p   p   p   p   p   p
Anti-CCP + (82%) 21 0.10 7 0.20 3.24 < 0.01 8 < 0.01 7 0.17 16 < 0.01 6 < 0.01 3 0.72 1 0.10 4 0.37
- (18%) 13 7 4.09 18 8 33 14 3 1.5 4.5
Fibβ 60–74 + (75%) 20 0.63 7 0.04 3.28 0.02 7 < 0.01 7 0.65 17 < 0.01 6 < 0.01 3 0.97 1 0.71 4.5 0.73
- (25%) 19 10 3.87 14 7 28 11 3 0.5 3.5
Vim 60–75 + (73%) 18 0.95 7 0.54 3.29 0.05 8 < 0.01 6 0.83 17 < 0.01 6 0.02 3 0.96 1 0.26 4.5 0.95
- (27%) 21 7 3.77 14 7 23 9 3 1 4
H4 31–50 + (67%) 21 0.39 8 0.65 3.27 0.01 8 < 0.01 6 0.03 17 0.01 6 0.01 3 0.88 1 0.94 4.5 0.70
- (33%) 17 7 3.84 13 10 21 9 3 0.75 3.25
CEP-1 + (65%) 21 0.13 8 0.93 3.32 0.35 9 0.06 7 0.47 17 0.03 6 0.12 3 0.76 1 0.46 4.5 0.54
- (35%) 17 6 3.36 11 7 21 7 3 0.5 3.5
Fil 307–324 + (63%) 21 0.15 8 0.70 3.29 0.06 7 < 0.01 7 0.54 17 0.01 6 < 0.01 3 0.94 1 0.98 4 0.91
- (37%) 17 7 3.64 13 7 21 9 3 1 4
Fibα 573 + (57%) 22 0.13 8 0.85 3.27 0.03 7 < 0.01 6 0.14 17 0.05 6 0.12 3 0.61 1 0.23 4.5 0.37
- (43%) 16 7 3.42 12 8 21 8 3 0.5 4
Fibβ 36–52 + (54%) 21 0.08 8 0.78 3.26 0.05 8 < 0.01 6 0.06 17 0.06 6 0.03 3 0.58 1 0.05 4.5 0.19
- (46%) 17 7 3.63 11 8 19 8 3 0.5 3.5
H3 1–30 + (49%) 18 0.97 7 0.40 3.29 0.48 8 0.09 6 1.00 17 0.04 6 0.09 3 0.62 0.5 0.04 4 0.16
- (51%) 20 7 3.37 10 7 19 7 3 1 4.5
H4 14–34 + (48%) 21 0.13 8 0.74 3.27 0.28 7 < 0.01 7 0.77 17 0.30 7 0.86 3 0.39 1 0.30 4 0.28
- (52%) 18 7 3.45 11 7 20 6 3 1 4.5
H3 21–44 + (44%) 22 0.09 9 0.21 3.31 0.69 9 0.07 7 0.84 17 0.28 6 0.41 3 0.68 0.5 0.14 4 0.32
- (56%) 18 6 3.36 10 7 19 7 3 1 4.5
Fibα 621–635 + (43%) 22 0.36 8 0.84 3.29 0.09 7 < 0.01 7 0.54 16 0.02 6 0.07 2.5 0.46 0.5 0.30 4 0.34
- (57%) 18 7 3.37 12 7 20 7 3 1 4.5
Vim 2–17 + (41%) 19 0.72 7 0.49 3.29 0.34 7 < 0.01 7 0.48 17 0.08 6 0.13 3 0.50 1 0.61 4 0.45
- (59%) 20 7 3.36 11 7 20 7 3 1 4
Fibα 36–50 + (36%) 20 0.73 8 0.86 3.29 0.68 8 0.04 7 0.46 17 0.08 6 0.05 3 0.84 0.5 0.29 4 0.59
- (64%) 19 7 3.41 11 7 19 7 3 1 4
Fibα 591 + (32%) 19 0.70 6 0.29 3.29 0.05 7 < 0.01 6 0.28 17 0.53 6 0.88 3 0.86 1 0.33 4.5 0.70
- (68%) 20 8 3.40 11 7 19 7 3 0.5 4
Fibβ 74 + (30%) 22 0.19 8 0.87 3.25 0.53 9 0.12 8 0.74 17 0.08 6 0.67 2.5 0.57 0.5 0.32 4 0.48
- (70%) 18 7 3.33 10 7 19 7 3 1 4
Fibβ 72 + (12%) 21 0.25 5 0.59 3.59 0.37 10 0.48 9 0.52 22 0.19 9 0.06 3 0.73 0.5 0.72 4 0.98
- (88%) 19 7 3.31 9 7 17 6 3 1 4
  1. Anti-citrullinated protein antibody (ACPA) reactivities are sorted by decreasing frequency in the cohort: p values (p) were derived from the Mann-Whitney U test; statistically significant differences are in italics
  2. Abbreviations: ESR erythrocyte sedimentation rate (millimetre/hour, 1–140), CRP C-reactive protein (milligram/litre), DAS Disease Activity Score (0–10), SJC swollen joint count (0–44), RAI Ritchie articular index (0–78), US ultrasound, GS grey scale (0–96), PD power Doppler (0–96), vdHSS van der Heijde modified Sharp score, E erosion (0–280), JSN joint space narrowing (0–168), T total (0–448), anti-CCP anti-cyclic citrullinated peptide, Fib fibrinogen, Vim vimentin, H histone, CEP-1 citrullinated enolase peptide-1, Fil filaggrin; numbers referring to amino acid sequence